MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment

Allergy. 2024 Sep;79(9):2558-2561. doi: 10.1111/all.16212. Epub 2024 Jul 2.

Authors

Ewa A Bartko¹, Maiken Mellergaard^{2

3}, Solveig S Groen^{4

5}, Signe Holm Nielsen⁴, Jesper Elberling¹, Aase Handberg^{2

3}, Lars K Poulsen¹, Lars H Blom¹, Bettina M Jensen¹

Affiliations

¹ Allergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark.
² Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
³ Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
⁴ ImmunoScience, Nordic Bioscience, Herlev, Denmark.
⁵ Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

PMID: 38953463
DOI: 10.1111/all.16212

No abstract available

Publication types

Letter

MeSH terms

Anti-Allergic Agents* / therapeutic use
Chemokines, CC / metabolism
Chronic Urticaria* / drug therapy
Collagen / metabolism
Female
Humans
Male
Matrix Metalloproteinase 9* / metabolism
Omalizumab* / therapeutic use
Treatment Outcome

Substances

Omalizumab
Matrix Metalloproteinase 9
Anti-Allergic Agents
Chemokines, CC
Collagen